Filter by Year:
Press Releases
-
Jan 03, 2024
Foghorn Therapeutics Announces CFO Departure
-
Dec 01, 2023
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
-
Nov 02, 2023
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
-
Oct 24, 2023
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
-
Oct 13, 2023
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
-
Oct 04, 2023
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
-
Sep 05, 2023
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Aug 31, 2023
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
-
Aug 08, 2023
Foghorn Therapeutics Announces Chief Medical Officer Succession
-
Aug 04, 2023
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
Displaying 21 - 30 of 91